Regeneron LAG-3 Melanoma Trial Misses Primary Endpoint

Regeneron Pharmaceuticals said on May 15 that its Phase 3 trial of fianlimab, an experimental LAG-3 inhibitor, combined with the PD-1 inhibitor cemiplimab did not reach statistical significance for progression-free survival against pembrolizumab monotherapy in first-line advanced melanoma. The high-dose combination produced a median PFS of 11.5 months compared with 6.4 months for pembrolizumab, a 5.1-month numeric improvement that came in just outside the prespecified significance threshold.

Key Takeaways

• Phase 3 trial in 1,546 patients with advanced melanoma compared fianlimab plus cemiplimab against pembrolizumab monotherapy as first-line therapy.
• High-dose combination produced median progression-free survival of 11.5 months versus 6.4 months for pembrolizumab, a 5.1-month numeric gain.
• The hazard ratio of 0.845 (95% CI 0.709-1.008, p=0.0627) narrowly missed the prespecified threshold for statistical significance.
• No new safety signals were reported, and a head-to-head trial against Opdualag, the only approved LAG-3 combination, is ongoing.

The trial enrolled 1,546 patients aged 12 and older with unresectable locally advanced or metastatic melanoma who had not received prior systemic therapy. Patients were randomized to a high-dose fianlimab combination (1600 mg fianlimab plus 350 mg cemiplimab every three weeks), a low-dose combination (400 mg fianlimab plus 350 mg cemiplimab), pembrolizumab monotherapy at 200 mg, or cemiplimab monotherapy at 350 mg, according to the company's May 15 release. Detailed data will be presented at an upcoming medical meeting.

What the LAG-3 Pathway Has Promised for Melanoma

LAG-3 is the third major immune checkpoint to enter melanoma therapy, after PD-1 and CTLA-4. The pathway acts as a brake on T-cell activity inside tumors. Blocking it is meant to reawaken exhausted T cells that PD-1 inhibition alone cannot fully recover, particularly in patients whose tumors carry markers of immune resistance.

The clinical precedent is Opdualag, the fixed-dose combination of nivolumab and relatlimab developed by Bristol Myers Squibb. The RELATIVITY-047 trial, published in the New England Journal of Medicine, showed that Opdualag more than doubled median progression-free survival compared with nivolumab alone, 10.1 months versus 4.6 months, and the FDA approved it in March 2022 as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. A four-year follow-up confirmed durable PFS benefit, with 4-year PFS rates of 30.6 percent for the combination versus 23.6 percent for nivolumab monotherapy.

Regeneron's trial was designed to extend that benefit to a broader population by pairing a new LAG-3 antibody with cemiplimab, the company's own PD-1 inhibitor marketed as Libtayo. The miss does not invalidate the pathway. It indicates that the specific combination, at the doses tested, did not clear the statistical bar that pembrolizumab monotherapy now sets.

What Does a Missed Endpoint With a 5.1-Month PFS Gain Actually Mean?

A hazard ratio of 0.845 with a p-value of 0.0627 is a near-miss, not a failure of effect. The 95 percent confidence interval of 0.709 to 1.008 just crosses one, meaning the data are statistically consistent with no benefit but also consistent with a meaningful reduction in disease progression risk. Regulators have approved drugs on similar profiles when supported by survival data or biomarker-defined subgroups.

The 5.1-month median PFS gap is the larger story for clinicians. Pembrolizumab is a high bar in this setting, and a numeric difference of that size in a 1,546-patient trial suggests the LAG-3 plus PD-1 mechanism is doing real work. The question is whether subgroup analyses, overall survival data, or the ongoing head-to-head comparison against Opdualag will turn the program into a regulatory case. Regeneron has continued the head-to-head trial, which is a signal that internal modeling supports a path forward.

For dermatologists who diagnose and monitor melanoma, the immediate takeaway is that the standard of care for first-line advanced disease does not change. Pembrolizumab and Opdualag remain the two most established immunotherapy options for unresectable or metastatic melanoma in 2026, and the past year has been a difficult one for new entrants. In November 2025, the FDA issued a complete response letter for Replimune's RP1 melanoma therapy, citing flaws in the IGNYTE trial design.

When Will the Next Readout Arrive?

Regeneron's ongoing Phase 3 head-to-head trial comparing the high-dose fianlimab combination against Opdualag is the program's most important near-term catalyst. A favorable result would give the FDA a head-to-head efficacy comparison rather than a placebo-adjusted one, which is the kind of evidence the agency increasingly prefers in crowded immunotherapy fields. The company has not disclosed the projected readout date.

Detailed data from the trial that missed will be presented at an upcoming medical meeting, where subgroup analyses and biomarker correlations are expected. Those data will determine whether Regeneron pursues a regulatory filing in a defined population or pivots resources toward the head-to-head study. For an educated skincare audience, the broader point is that melanoma immunotherapy is still expanding, even when individual trials stumble. JAMA Dermatology projects that the global skin cancer burden will roughly double by 2050, which makes the prevention case stronger every year. The clinical ceiling on advanced disease keeps rising, but the most reliable form of long-range insurance is still consistent broad-spectrum sun protection.